Pediatric mania and second-generation antipsychotics: Efficacy, administration, and side effects
- David Axelson, MD
David Axelson, MD
- Professor of Psychiatry
- The Ohio State University College of Medicine
For children and adolescents with mania, second-generation antipsychotics are often efficacious and thus frequently prescribed. As an example, a nationally representative survey of outpatient visits for bipolar disorder in the United States between 2005 and 2009 found that in adolescents, antipsychotics were prescribed in 29 percent of the visits . In younger children, antipsychotics were prescribed in 12 percent of the visits.
This topic reviews the efficacy, administration, and side effects of second-generation antipsychotics in youth with mania. Other aspects of pediatric bipolar disorder are discussed separately, including an overview of choosing treatment; general principles of using pharmacotherapy; the efficacy and core elements of adjunctive psychotherapy; assessment and diagnosis; and the epidemiology, clinical features, and course of illness:
- Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69:1247.
- Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70:1441.
- Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70:756.
- Findling RL, Kauffman R, Sallee FR, et al. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 2009; 19:431.
- Thomas T, Kuich KW, Findling RL. Bipolar disorders. In: Clinical Manual of Child and Adolescent Psychopharmacology, Second Edition, McVoy M, Findling RL. (Eds), American Psychiatric Publishing, Washington, DC 2013. p.227.
- NICE: National Institute for Health and Care Excellence. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. July 2013. http://www.nice.org.uk/guidance/TA292 (Accessed on December 04, 2014).
- Findling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord 2013; 15:138.
- Findling RL, Landbloom RL, Szegedi A, et al. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:1032.
- Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164:1547.
- Olsen BT, Ganocy SJ, Bitter SM, et al. Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine. Compr Psychiatry 2012; 53:1000.
- McCormack PL. Olanzapine: in adolescents with schizophrenia or bipolar I disorder. CNS Drugs 2010; 24:443.
- Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009; 19:539.
- Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012; 22:157.
- Joshi G, Petty C, Wozniak J, et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology (Berl) 2013; 227:449.
- Pathak S, Findling RL, Earley WR, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry 2013; 74:e100.
- DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45:305.
- Scheffer RE, Tripathi A, Kirkpatrick FG, Schultz T. Rapid quetiapine loading in youths with bipolar disorder. J Child Adolesc Psychopharmacol 2010; 20:441.
- Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11:687.
- Pavuluri MN, Henry DB, Findling RL, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010; 12:593.
- Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012; 69:515.
- Salpekar JA, Joshi PT, Axelson DA, et al. Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study. J Am Acad Child Adolesc Psychiatry 2015; 54:999.
- Walkup JT, Wagner KD, Miller L, et al. Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment. J Am Acad Child Adolesc Psychiatry 2015; 54:1008.
- Fu-I L, Boarati MA, Stravogiannis A, Wang YP. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series. J Clin Psychiatry 2009; 70:604.
- Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 Suppl 4:26.
- Findling RL, Cavuş I, Pappadopulos E, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2013; 23:545.
- Jensen KG, Juul K, Fink-Jensen A, et al. Corrected QT changes during antipsychotic treatment of children and adolescents: A systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 2014.
- Correll CU, Lops JD, Figen V, et al. QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry 2011; 72:854.
- Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. Pediatr Clin North Am 2011; 58:173.
- Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002; 12:93.
- Kowatch RA, Suppes T, Gilfillan SK, et al. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. J Child Adolesc Psychopharmacol 1995; 5:241.
- Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:213.
- Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs 2010; 24:575.
- Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.
- Varley CK, McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA 2009; 302:1811.
- Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012; 129:e771.
- Arango C, Giráldez M, Merchán-Naranjo J, et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry 2014; 53:1179.
- Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387:1561.
- McClellan J, Kowatch R, Findling RL, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:107.
- NICE National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. September 2014. http://www.nice.org.uk/guidance/CG185 (Accessed on November 18, 2014).
- Andrade SE, Lo JC, Roblin D, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics 2011; 128:1135.
- Nielsen RE, Laursen MF, Vernal DL, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study. J Am Acad Child Adolesc Psychiatry 2014; 53:971.
- Shain BN, COMMITTEE ON ADOLESCENCE. Collaborative role of the pediatrician in the diagnosis and management of bipolar disorder in adolescents. Pediatrics 2012; 130:e1725.
- Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69:1157.
- Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007; 17:647.